Target Name: MCC
NCBI ID: G4163
Review Report on MCC Target / Biomarker Content of Review Report on MCC Target / Biomarker
MCC
Other Name(s): MCC variant 1 | MCC variant 2 | MCC1 | Colorectal mutant cancer protein isoform 1 | CRCM_HUMAN | MCC regulator of WNT signaling pathway | mutated in colorectal cancers | MCC regulator of WNT signaling pathway, transcript variant 1 | Protein MCC | FLJ38893 | MCC, WNT signaling pathway regulator | Colorectal mutant cancer protein | Colorectal mutant cancer protein isoform 2 | MCC regulator of WNT signaling pathway, transcript variant 2 | FLJ46755

MCC: A Protein Involved in The Immune Response and Cell Growth

MCC, or MCC variant 1, is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and kidneys. It is a member of the MHC class I molecules, which are responsible for presenting antigens from the immune system to T cells. MCC is also known as HLA-DP.

MCC is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. The C regions contain the major histocompatibility determinant (MHC) genes, which are responsible for presenting antigens from the immune system to T cells.

MCC is expressed in a variety of tissues throughout the body, including the brain, heart, lungs, and kidneys. It is also expressed in the testes and thymus, which are responsible for the production of T cells. MCC is primarily expressed in the brain, where it is involved in the immune response.

One of the functions of MCC is to present antigens from the immune system to T cells. When an antigen enters the body, it is engulfed by MCC, which then travels to the T cell and presents it to the cell through its MHC class I molecules. T cells then respond to the antigen by either activating and multiplying, or by presenting the antigen to other immune cells and activating them. This is an important part of the immune response, as T cells are responsible for detecting and responding to foreign substances in the body.

MCC is also involved in the regulation of the immune response. For example, it has been shown to play a role in the regulation of inflammation, as well as the control of cell proliferation.

MCC is a potential drug target in the treatment of various diseases. For example, MCC has been shown to be involved in the development of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. It has also been shown to be involved in the regulation of cancer cell growth and survival.

In addition to its role in the immune response, MCC may also be a potential biomarker for certain diseases. For example, MCC has been shown to be involved in the regulation of inflammation in the brain, which may be an important factor in the development of neurodegenerative diseases. It may also be involved in the regulation of pain, which may be an important factor in the development of chronic pain.

Overall, MCC is a protein that is involved in a variety of processes throughout the body, including the immune response and the regulation of cell growth and survival. It is a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of MCC in the immune response and its potential as a drug.

Protein Name: MCC Regulator Of WNT Signaling Pathway

Functions: Candidate for the putative colorectal tumor suppressor gene located at 5q21. Suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. Inhibits DNA binding of b-catenin/TCF/LEF transcription factors. Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase (PAK) activation (PubMed:18591935, PubMed:19555689, PubMed:22480440). Represses the beta-catenin pathway (canonical Wnt signaling pathway) in a CCAR2-dependent manner by sequestering CCAR2 to the cytoplasm, thereby impairing its ability to inhibit SIRT1 which is involved in the deacetylation and negative regulation of beta-catenin (CTNB1) transcriptional activity (PubMed:24824780)

The "MCC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MCCC1 | MCCC2 | MCCD1 | MCCD1P1 | MCEE | MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29